Cat. No.: HY-15312

WP1066

39 Cited Publications

Customer Review

Based on 39 publication(s) in Google Scholar

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3. WP1066 can cross the blood-brain barrier[1][2][3][4].

For research use only. We do not sell to patients.

Purity: 99.53%
CAS No.: 857064-38-1
Formula: C₁₇H₁₄BrN₃O
Molecular Weight:356.22

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

WP1066 Chemical Structure

CAS No.: 857064-38-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (39)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3. WP1066 can cross the blood-brain barrier[1][2][3][4].

IC₅₀ & Target^[1]^[2]

JAK2

STAT3

All STAT Isoforms :

All JAK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	4.2 μM Compound: WP1066	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay	[PMID: 34055214]
U-266	IC₅₀	1.5 μM Compound: WP1066	Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay	[PMID: 22036213]
U-373MG ATCC	IC₅₀	3.7 μM Compound: WP1066	Antitumor activity against human U373MG cells after 24 to 72 hrs by MTT assay Antitumor activity against human U373MG cells after 24 to 72 hrs by MTT assay	[PMID: 22036213]
U-87MG ATCC	IC₅₀	5.6 μM Compound: WP1066	Antitumor activity against human U87MG cells after 24 to 72 hrs by MTT assay Antitumor activity against human U87MG cells after 24 to 72 hrs by MTT assay	[PMID: 22036213]

In Vitro

WP1066 markedly inhibits the growth of HEL cells in a dose-dependent manner. The IC₅₀ value for inhibition of the proliferation of HEL cells is 2.3 μM. WP1066 inhibits the growth of human HEL cells carrying the JAK2 V617F mutant isoform^[1]. Blockade of p-STAT3 with WP1066 enhances the cytotoxic effects of CTX on the tumor. The IC₅₀ doses of WP1066 for B16 cells is 2.43 μM (0.865 μg/mL)^[2]. WP1066 inhibits AML blast colony-forming cell proliferation, suppresses normal BM progenitor proliferation at increased concentrations, and inhibits AML colony-forming cell proliferation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

WP1066 (30 mg/kg, o.g.) exerts an additive effect to CTX inhibition of the p-STAT3 pathway within the tumor microenvironment^[2].
WP1066 shows excellent CNS penetration provided compelling rationale for testing WP1066 against a variety cancer^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 857064-38-1
Appearance Solid
Molecular Weight 356.22
Formula C₁₇H₁₄BrN₃O
Color White to light yellow
SMILES

O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (39)

All WB

Sort by:

Journal Impact Factor

Cell Metab

Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. [Abstract]

2023 Oct 3;35(10):1688-1703.e10. PMID: 37793345
Adv Sci (Weinh)

CCDC80 Protects against Aortic Dissection and Rupture by Maintaining the Contractile Smooth Muscle Cell Phenotype. [Abstract]

2025 Apr 25:e2502108. PMID: 40278823
J Clin Invest

Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. [Abstract]

2026 Mar 17:e199056. PMID: 41842961
J Clin Invest

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. [Abstract]

2024 Jun 17;134(12):e175033. PMID: 38941297
J Exp Clin Cancer Res

CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD+/NADH ratio. [Abstract]

2025 Jan 3;44(1):3. PMID: 39754188
Sci Adv

JAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells. [Abstract]

2024 Mar 22;10(12):eadl0368. PMID: 38507500
Adv Healthc Mater

Dual-Barb Microneedle with JAK/STAT Inhibitor-Loaded Nanovesicles Encapsulation for Tendinopathy. [Abstract]

2024 Jul 19:e2401512. PMID: 39030889
Cell Death Dis

SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. [Abstract]

2021 Jun 2;12(6):570. PMID: 34108444
Acta Neuropathol

Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. [Abstract]

2021 Sep;142(3):537-564. PMID: 34302498
Acta Pharmacol Sin

ZYZ-803, a novel hydrogen sulfide-nitric oxide conjugated donor, promotes angiogenesis via cross-talk between STAT3 and CaMKII. [Abstract]

2020 Feb;41(2):218-228. PMID: 31316179

WP1066 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2020 Feb;41(2):218-228. [Abstract]

HUVECs are pretreated with WP1066 for 1 h, followed by ZYZ-803 (1 μM) for 30 min. Protein levels are assessed by Western blot.
Free Radic Biol Med

Mechanism of cigarette smoke in promoting small airway remodeling in mice via STAT 3 / PINK 1-Parkin / EMT. [Abstract]

2024 Aug 28:S0891-5849(24)00630-0. PMID: 39214258
Free Radic Biol Med

SERPINB1 ameliorates acute lung injury in liver transplantation through ERK1/2-mediated STAT3-dependent HO-1 induction. [Abstract]

2017 Jul:108:542-553. PMID: 28427999

WP1066 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2017 Jul:108:542-553. [Abstract]

The role of STAT3 in SERPINB1-mediated protecting ALI in OALT is further confirmed by using STAT3 specific inhibitor WP1066. post-OALT lung STAT3 activation is significantly increased evidenced by elevated phosphorylation of STAT3 at site727 and site705 (P<0.01 vs sham), which are associated with enhanced HO-1 protein expression.
J Transl Med

FNDC5 attenuates obesity-induced cardiac hypertrophy by inactivating JAK2/STAT3-associated inflammation and oxidative stress. [Abstract]

2019 Apr 2;17(1):107. PMID: 30940158
Oncogene

HERC1 oncogene enhances stemness and tumorigenic potential in CD44+-derived organoids of head and neck squamous cell carcinoma through IL-6/STAT3 signaling. [Abstract]

2026 May;45(19):1840-1855. PMID: 41965446
Br J Cancer

Apolipoprotein D is crucial for promoting perineural invasion in salivary adenoid cystic carcinoma. [Abstract]

2025 Apr;132(7):599-610. PMID: 39962257
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
OncoImmunology

Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling. [Abstract]

2021 Nov 23;10(1):2004659. PMID: 34858728
Biochem Pharmacol

WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin. [Abstract]

2024 Mar:221:116040. PMID: 38311257
Cells

Nootkatone Derivative Nootkatone-(E)-2-iodobenzoyl hydrazone Promotes Megakaryocytic Differentiation in Erythroleukemia by Targeting JAK2 and Enhancing JAK2/STAT3 and PKCδ/MAPK Crosstalk. [Abstract]

2024 Dec 26;14(1):10. PMID: 39791711
Life Sci

PSME2 promotes malignant progression through autophagy modulation via IL-6/STAT3 signaling pathway in esophageal squamous cell carcinoma. [Abstract]

2025 May 20:123749. PMID: 40404117
Cancer Immunol Immunother

Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer. [Abstract]

2022 Jun 20. PMID: 35725835
Life Sci

Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis. [Abstract]

2021 Jan 1;264:118677. PMID: 33129875
Int J Mol Sci

In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. [Abstract]

2022 Apr 12;23(8):4277. PMID: 35457095
Eur J Pharmacol

Carnosol inhibits influenza A virus by disrupting the viral envelope and interfering with Jak2/STAT3 signaling pathway. [Abstract]

2025 Apr 9:177606. PMID: 40216182
Hepatol Commun

PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18. [Abstract]

2025 Mar 24;9(4):e0647. PMID: 40130992
Exp Neurol

Apelin-13 attenuates microglia-mediated neuroinflammation following intracerebral hemorrhage via targeting JAK2/STAT3 signaling pathway. [Abstract]

2025 Dec 31:398:115633. PMID: 41482108
FEBS J

TNF-α/ENO1 signaling facilitates testicular phagocytosis by directly activating Elmo1 gene expression in mouse Sertoli cells. [Abstract]

2022 May;289(10):2809-2827. PMID: 34919331
Sci Rep

Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer. [Abstract]

2025 May 15;15(1):16869. PMID: 40374882
J Biol Chem

Exogenous L-fucose attenuates depression induced by chronic unpredictable stress: implicating core fucosylation has an antidepressant potential. [Abstract]

2025 Jan 24:108230. PMID: 39864626
Oncol Rep

SOX12 contributes to the activation of the JAK2/STAT3 pathway and malignant transformation of esophageal squamous cell carcinoma. [Abstract]

2021 Jan;45(1):129-138. PMID: 33416144
Cell Cycle

YAP1, targeted by miR-375, enhanced the pro-angiogenesis of airway smooth muscle cells in asthma via STAT3 activation. [Abstract]

2020 Jun;19(11):1275-1284. PMID: 32308108
J Cancer

B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. [Abstract]

2017 Feb 25;8(5):816-824. PMID: 28382144

WP1066 purchased from MedChemExpress. Usage Cited in: J Cancer. 2017 Feb 25;8(5):816-824. [Abstract]

The protein expression levels of p-Akt, t-Akt, p-STAT3, t-STAT3, MMP2 and MMP9 are determined via western blotting 48 h after knockdown of B7-H3 and blockade of the PI3K/Akt pathway using LY294002 or the STAT3 pathway using WP1066.
Pflugers Arch

Unlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenase. [Abstract]

2024 Dec;476(12):1913-1928. PMID: 39347835
Breast Cancer

PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. [Abstract]

2019 Sep;26(5):663-671. PMID: 30989585
Cancer Manag Res

Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway. [Abstract]

2018 Nov 26:10:6339-6355. PMID: 30568496

WP1066 purchased from MedChemExpress. Usage Cited in: Cancer Manag Res. 2018 Nov 26:10:6339-6355. [Abstract]

Western blotting analysis: treatment with the Stat3 inhibitor WP1066 neutralizes the up-regulation of MMP2 and MMP9 and reverses the EMT progression caused by the overexpression of Uck2 in Bel-7402 cells.
Biotechnol Lett

Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition. [Abstract]

2020 Oct;42(10):2049-2058. PMID: 32500474
BMC Pediatr

Butyrate inhibits histone deacetylase 2 expression to alleviate liver fibrosis in biliary atresia. [Abstract]

2025 Apr 12;25(1):286. PMID: 40221650
Biol Pharm Bull

Anti-neuroinflammatory Effects of Active Compound SPA1413 via Suppression of the MAPK and JAK/STAT Signaling Pathways. [Abstract]

2023 Aug;46(11):1517-1526. PMID: 37914355
Am J Transl Res

Resveratrol improves cardiac function by promoting M2-like polarization of macrophages in mice with myocardial infarction. [Abstract]

2019 Aug 15;11(8):5212-5226. PMID: 31497235

Solvent & Solubility

In Vitro:

DMSO : ≥ 44 mg/mL (123.52 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 16.67 mg/mL (46.80 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8073 mL

14.0363 mL

28.0725 mL

5 mM

0.5615 mL

2.8073 mL

5.6145 mL

10 mM

0.2807 mL

1.4036 mL

2.8073 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (14.04 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

Briefly, fresh low-density peripheral blood cells and various cell lines at the logarithmic phase of their growth are washed twice in RPMI 1640 containing 10% FCS and counted in a hemocytometer. Cell viability is assessed by the trypan blue (0.1%) staining method. Equal numbers of viable cells (5×10⁴ per well) are incubated in a total volume of 100 μL of RPMI 1640 supplemented with 10% FCS alone or with WP1066 at increasing concentrations; the incubations are continued for up to 72 h in 96-well flat-bottomed plates at 37°C in a humidified 5% CO₂ atmosphere. Experiments for each condition are done in triplicate. After incubation, 20 μL of CellTiter96 One Solution Reagent are added to each well. The plates are then incubated for an additional 60 min at 37°C in a humidified 5% CO₂ atmosphere. Immediately after incubation, absorbance is read using a 96-well plate reader at a wavelength of 490 nm.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

To ascertain the inhibition of the immune populations within the spleen and peripheral blood compartments, tumor-bearing mice are treated with CTX, WP1066, or CTX in combination with WP1066, for 14 days. Single-cell suspensions are prepared from spleens and the peripheral blood of mice and single cells are surface-stained with FITC-conjugated anti-CD4 (L3T4) or PE-conjugated anti-CD8 (53-6.7) and are intracellularly stained with APC-conjugated-FoxP3 (clone FJK-16s). The cell number of CD4⁺ and CD8⁺ T cells in the peripheral blood is counted based on positive surface staining of the respective markers relative to the total cell count of PBMCs. The percentage of FoxP3+ Tregs is calculated within the peripheral blood and within the CD4 compartment.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Verstovsek S, et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res, 2008, (3), 788-796. [Content Brief]

[2]. Hatiboglu MA, et al. The tumor microenvironment expression of p-STAT3 influences the efficacy of WP1066 in murine melanoma models. Int J Cancer, 2012, 131(1), 8-17 [Content Brief]

[3]. Ferrajoli A, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res, 2007, 67(23), 11291-11299. [Content Brief]

[4]. Kong L Y, et al. A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2008, 14(18): 5759.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.8073 mL	14.0363 mL	28.0725 mL	70.1813 mL
	5 mM	0.5615 mL	2.8073 mL	5.6145 mL	14.0363 mL
	10 mM	0.2807 mL	1.4036 mL	2.8073 mL	7.0181 mL
	15 mM	0.1872 mL	0.9358 mL	1.8715 mL	4.6788 mL
	20 mM	0.1404 mL	0.7018 mL	1.4036 mL	3.5091 mL
	25 mM	0.1123 mL	0.5615 mL	1.1229 mL	2.8073 mL
	30 mM	0.0936 mL	0.4679 mL	0.9358 mL	2.3394 mL
	40 mM	0.0702 mL	0.3509 mL	0.7018 mL	1.7545 mL
DMSO	50 mM	0.0561 mL	0.2807 mL	0.5615 mL	1.4036 mL
	60 mM	0.0468 mL	0.2339 mL	0.4679 mL	1.1697 mL
	80 mM	0.0351 mL	0.1755 mL	0.3509 mL	0.8773 mL
	100 mM	0.0281 mL	0.1404 mL	0.2807 mL	0.7018 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

WP1066

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Cysteine Targeted Covalent Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) WP1066

All STAT Isoforms

All JAK Isoforms

Biological Activity

Chemical Information

Publications (39)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

WP1066 Related Classifications

Cat. No.: HY-15312